Career Profile

  • Accomplished pharmaceutical CMC and Technical Operations executive with board level experience and a proven track record of small molecule drug development from inception to regulatory approval and commercialization.
  • Adept at overseeing complex projects from conception to execution, optimizing processes, and ensuring seamless cross-functional collaboration.
  • Proven track record of implementing innovative solutions, enhancing efficiency, and achieving cost savings.
  • Globally recognized for expertise and deep understanding of CMC, small molecule Process Development, Manufacturing, Scale-up, Quality, Regulatory, Supply Chain Operations, and Strategic Sourcing.
  • Experienced leading regulatory filings, IND, NDA, MAA. Subject matter expert, experienced with FDA audits including PAI audits.
  • Established leader with a highly professional attitude, high reliability, and high regard for fellow personnel, and committed to empowering, developing and retaining talent.
  • Demonstrated success in leadership roles within high-growth companies.

Experience

Vice President, Technical Operations

2020 - 2024
Neumora Therapeutics, Watertown, MA
  • Expansion of role to cover more assets through the acquisition of BlackThorn by Neumora including the recruiting of talent for the expanded team.
  • Served on Executive team to help shape company strategy.
  • Led CMC team to support the successful completion of NMRA-140 Phase 2 studies and the initiation of the Phase 3 program, including completion of registration stability.
  • Established and agile and flexible supply chain network to support Neumora development programs.
  • Led CMC technical team to transition multiple pre-clinical assets to the IND stage and support subsequent clinical studies from Phase 1 to Phase 2.

Vice President, Technical Operations

2019 - 2020
BlackThorn Therapeutics, San Francisco, CA

Head of CMC

2018 - 2019
BlackThorn Therapeutics, San Francisco, CA
  • Led activities related to small molecule drug substance and solid oral drug product process development, including process optimization, cGMP manufacture of Drug Substance (DS) and Drug Product (DP), Analytical Development and Quality Control, regulatory filings (multiple INDs), strategic sourcing and supply chain management, in support of new and ongoing BlackThorn neuroscience small molecule clinical programs.
  • Responsible for BlackThorn CMC strategy, project plans, budgets, schedules, and timelines to ensure successful project completion.

Executive Director

2015 - 2018
Relypsa, a Vifor Pharma Company, Redwood City, CA

Senior Director

2012 - 2015
Relypsa, a Vifor Pharma Company, Redwood City, CA
  • Guided a large multi-disciplinary team through the Veltassa development program and commercialization, including process validation, strategic sourcing, regulatory filing and approval (NDA,MAA) in the US and EU, Canada, Australia, Israel and Switzerland.
  • Veltassa is a novel polymeric drug developed for the treatment of hyperkalemia.
  • Developed world wide supply chain to enable the sourcing of key materials worldwide at multi metric ton scale.
  • Led activities to develop and implement a continuous manufacturing process to enhance manufacturing efficiency and lower cost of goods, including engineering and facility design, environmental issues, contract negotiations, as well as interactions with the FDA Emerging Technology (ETT) team.

Director, Process Engineering

2010 - 2012
Exelixis, South San Francisco, CA

Associate Director, Process Engineering

2009 - 2010
Exelixis, South San Francisco, CA

Senior Scientist

2007 - 2009
Exelixis, South San Francisco, CA
  • Guided a multi-disciplinary team (Process Development, Analytical Development, Sourcing and Supply Chain) through from the initial lab development stages to successful process validation, NDA approval and commercialization for the cabozantinib (Cometriq) small molecule oncology franchise.
  • Established the Process Engineering function at Exelixis, recruited talent and led/provided support for several small molecule development compounds in the Exelixis oncology pipeline.
  • Led the team through evaluation and outsourcing activities for multiple Exelixis oncology compounds including Cabozantinib.

Senior Research Investigator I, Process Research and Development

2004 - 2007
Bristol-Myers Squibb Co., New Brunswick, NJ

Research Investigator II, Process Research and Development

2000 - 2004
Bristol-Myers Squibb Co., New Brunswick, NJ
  • Held positions of increasing responsibility in the small molecule process development department. Served as the project leader for two candidates in the BMS p38 program where I led interdisciplinary teams through initial Phase I development activities, scale-up and manufacturing, through to a successful IND filing and subsequent Phase II process development.
  • Additionally, held CMC lead roles for several candidates in the BMS PPAR program for the treatment of diabetes, the BMS HMG-CoA program for cholesterol lowering, as well as the BMS CRF-1 antagonist program.
  • Senior process engineer for the Onglyza (Saxagliptin) and contributed to the development of Sprycel (Dasatinib) for the treatment of leukemia.

Selected Publications

Sterilization Processes in the Pharmaceutical Industry - by: Piero Armenante and Otute Akiti, Chapter in Chemical Engineering in the Pharmaceutical Industry: Drug Product Design, Development, and Modeling, 2nd Edition, Wiley 2019.
Mixing and Processes Validation in the Pharmaceutical Industry - by: Otute Akiti and Piero Armenante, Chapter in Advances in Industrial Mixing: A Companion to the Handbook of Industrial Mixing, Wiley 2015.
Development of a Scaleable Process for the Synthesis of a Next-Generation Statin - Lindsay A. Hobson, Otute Akiti, et al, Organic Process Research and Development, (2010), pp 441-458
Hydrodynamic Effects of Mixing and Competitive Reactions in Laboratory Reaction Vessels - Otute Akiti, Agnes Yeboah, Ge Bai and Piero Armenante, Chemical Engineering Science, 60(2005), pp 2341-2354.
Experimentally validated micro-mixing based for fed-batch stirred reactors - Otute Akiti and Piero M. Armenante, AIChE Journal, 50(3) , pp 566 – 577

Professional Affiliations

American Insitute of Chemical Engineers

1992 - Present
Active in Pharmaceutical Division Planning Activities

  • Past Program Chair for Pharmaceutical Division
  • Regularly chair several sessions at annual meetings
  • North American Mixing Forum (NAMF)

    1998 - Present
    Active in Program Planning and Chairing Sessions and setting new directions for NAMF

  • President Emeritus: 2016 - Present
  • NAMF President: 2014 – 2016
  • NAMF Vice President: 2012 – 2014
  • NAMF Secreatry: 2007 – 2012
  • International Society of Pharmaceutical Engineers (ISPE)

    2007 - Present

    Patents